Literature DB >> 33768075

Synchronous Lung Adenocarcinoma and Papillary Thyroid Carcinoma The Metastases at the Centre of the Discussion.

Joana Ferra1, Cátia Guimarães1, Cristina Matos1, Fernando Nogueira1.   

Abstract

Synchronous tumours are defined as two or more independent primary neoplasms of different origins diagnosed at the same time in 1 individual. Although rare, its incidence is increasing and the proper diagnosis and staging of each tumour is crucial in defining the patient prognosis and the best therapeutic choice. We present a case of a 56-year-old woman presenting with a lung adenocarcinoma and pulmonary metastases initially diagnosed as stage IV and who was started on a tyrosine kinase inhibitor (erlotinib). In the meantime, she was also diagnosed with papillary thyroid carcinoma and was submitted to complete thyroidectomy. After 6 cycles of erlotinib, thoracic CT showed a decrease in the dimensions of the primary pulmonary tumour, but an increase in the size and number of pulmonary metastases while blood tests showed elevated thyroglobulin. This therefore raised the possibility that the metastases could have originated from the thyroid carcinoma. Anatomo-pathological examination of the lung metastases confirmed this hypothesis. In conclusion, it is important to confirm the origin of metastases in synchronous tumours given this can lead to a re-staging of tumours and a different prognosis, along with other therapeutic options. A multidisciplinary team meeting is crucial to define management and therapeutic approaches for these patients. LEARNING POINTS: Although rare, synchronous primary tumours are a possibility and physicians should be aware of this possibility.Papillary thyroid carcinoma may metastasize to the lungs and its differential diagnosis should be made in the presence of lung carcinoma.When in doubt, anatomo-pathological examination of the metastases should be performed for proper staging of both tumours and to decide on the best therapeutic option. © EFIM 2021.

Entities:  

Keywords:  Synchronous tumours; lung adenocarcinoma; lung metastases; papillary thyroid carcinoma

Year:  2021        PMID: 33768075      PMCID: PMC7977054          DOI: 10.12890/2021_002289

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  4 in total

Review 1.  Thyroid carcinoma.

Authors:  Steven I Sherman
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

Review 2.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

3.  Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors.

Authors:  Sun Wook Cho; Hoon Sung Choi; Gye Jeong Yeom; Jung Ah Lim; Jae Hoon Moon; Do Joon Park; June-Key Chung; Bo Youn Cho; Ka Hee Yi; Young Joo Park
Journal:  Thyroid       Date:  2013-09-11       Impact factor: 6.568

4.  Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program.

Authors:  Karynsa Cetin; David S Ettinger; Yong-Jiang Hei; Cynthia D O'Malley
Journal:  Clin Epidemiol       Date:  2011-04-28       Impact factor: 4.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.